mllt11 Antibody

What is MLLT11 and what are its key biological functions?

MLLT11 (Myeloid/lymphoid or mixed-lineage leukemia; translocated to chromosome 11/All1 Fused Gene From Chromosome 1q), also known as AF1Q, is a protein involved in transcriptional regulation with a molecular mass of approximately 68 kDa . It functions as a cofactor for the transcription factor TCF7 and plays a crucial role in regulating lymphoid development by driving multipotent hematopoietic progenitor cells toward a T cell fate . Recent studies have revealed MLLT11's important role in the migration and neurite outgrowth of callosal projection neurons during mouse brain formation . This multifunctional protein has also been identified as a potential prognostic biomarker in gliomas, with expression patterns correlating with various pathological features and immune cell infiltration in the tumor microenvironment .

What are the predicted molecular weights of MLLT11 in Western blotting?

When conducting Western blot analysis using MLLT11 antibodies, researchers should expect to observe bands at approximately 10 kDa and 36 kDa . These size variations may reflect different isoforms or post-translational modifications of the protein. When working with specific cell lines, such as Jurkat, K562, or Molt4, consistent band patterns have been observed at these molecular weights using validated antibodies like ab109016 . Variations in band patterns across different tissue types should be carefully documented as they may provide insights into tissue-specific processing or modifications of MLLT11.

Which cell or tissue types are optimal for studying MLLT11 expression?

Based on current research, several cell types have demonstrated reliable MLLT11 expression for experimental studies. For in vitro work, Jurkat, K562, and Molt4 cell lines have been successfully used for Western blotting applications . For tissue-based studies, cortical neurons exhibit physiologically relevant MLLT11 expression, particularly during developmental stages . In pathological contexts, glioma tissue samples of varying grades show differential expression of MLLT11, making them valuable for studying its role in cancer progression . When designing experiments, researchers should consider the biological context of their research question, as MLLT11 expression patterns may vary significantly between normal and pathological tissues.

What are the recommended dilutions and protocols for Western blotting using MLLT11 antibodies?

For optimal Western blotting results with MLLT11 antibodies, the following protocol has been validated:

• Sample preparation: Separate protein samples on 8% SDS-PAGE gels for 1 hour at 120V

• Transfer: Overnight transfer at 20V onto PVDF membranes

• Antibody dilutions:

  • Primary antibody: Anti-MLLT11 (1:1000 to 1:2000 dilution, Abcam ab109016)

  • Secondary antibody: Goat anti-rabbit HRP (1:5000 dilution)

• Detection: Develop with ECL substrate and image using standard chemiluminescence detection systems

Protein loading should be approximately 10 μg per lane for cell lysates, with β-actin typically used as an internal reference for normalization . For quantitative analysis, researchers should perform band densitometry using image analysis software such as ImageJ or Image Lab Software (Bio-Rad) .

What protocols are most effective for immunohistochemical detection of MLLT11?

For immunohistochemical detection of MLLT11 in tissue sections, the following protocol has demonstrated reliable results:

• Sample preparation:

  • Fix tissues with formalin and embed in paraffin

  • Section tissues at 4 μm thickness

  • Dewax and rehydrate sections

  • Perform antigen retrieval in citrate buffer

  • Quench endogenous peroxidase with 3% hydrogen peroxide (H₂O₂)

• Antibody staining:

  • Block nonspecific binding with 10% normal goat serum

  • Incubate sections overnight with MLLT11 primary antibody (1:100 dilution, Abcam ab109016) at 4°C

  • Incubate with secondary antibody (goat anti-rabbit IgG, 1:5000)

  • Develop with diaminobenzidine tetrahydrochloride (DAB)

  • Counterstain with hematoxylin

For quantitative analysis, IHC images should be acquired and scored using image processing software such as ImageJ to ensure objective assessment of MLLT11 protein expression levels .

What qPCR protocols are recommended for MLLT11 mRNA expression analysis?

For accurate quantification of MLLT11 mRNA expression, the following qPCR protocol has been validated:

• RNA extraction:

  • Extract total RNA using TRIzol or RNeasy Micro kit (QIAGEN)

  • Purify RNA using standard RNA purification kits

• cDNA synthesis:

  • Reverse transcribe RNA to cDNA using SuperScript II Reverse Transcriptase kit (Invitrogen) or equivalent

• qPCR reaction:

  • Use SYBR Green-based detection method

  • Perform reactions in triplicates with a total reaction volume of 20 μl

  • PCR conditions: 95°C for 15 min, followed by 40 cycles at 95°C for 15s and 60°C for 1 min

• Primer sequences:

  • MLLT11 forward: 5'-GTAGCCAGTACAGTTCCTTTCT-3'

  • MLLT11 reverse: 5'-AAGTTGAAGGTGCTGTACTCAA-3'

  • Alternative primers: 5'-GAACTGGATCTGTCGGAGCT-3' (forward) and 5'-GCGCTCTCCAGAAGTTGAAG-3' (reverse)

• Internal control:

  • GAPDH forward: 5'-ACCACAGTCCATGCCATCAC-3'

  • GAPDH reverse: 5'-TCCACCACCCTGTTGCTGTA-3'

• Analysis method:

  • Calculate relative expression using the 2^(-ΔΔCT) method with β-actin or GAPDH as reference genes

How can MLLT11 antibodies be used to study protein-protein interactions?

For investigating MLLT11's interactions with other proteins, co-immunoprecipitation (co-IP) techniques have been successfully employed using the following approach:

• Sample preparation:

  • Transfect cells with myc-tagged MLLT11 or control constructs

  • Prepare cell lysates in appropriate lysis buffer

• Immunoprecipitation:

  • Use EZview Red Anti-c-myc-agarose beads for immunoprecipitation

  • Incubate overnight at 4°C with gentle agitation

  • Wash beads thoroughly to remove non-specific binding

• Elution and analysis:

  • Elute proteins from the resin with 50 mM NaOH

  • Neutralize with 1 M Tris, pH 9.5

  • Add to nonreducing sample buffer for Western blot analysis

  • Detect potential binding partners using specific antibodies

This methodology has been instrumental in identifying MLLT11's functional interactions with proteins involved in cortical neuron development and may be adapted to study its interactions in other cellular contexts.

How can researchers investigate the relationship between MLLT11 expression and immune cell infiltration in tumors?

To study the relationship between MLLT11 expression and immune cell infiltration in tumor microenvironments, the following multi-modal approach is recommended:

• Bioinformatic analysis:

  • Utilize CIBERSORT deconvolution algorithm with LM22 signature matrices to analyze the relative abundance of infiltrating immune cells

  • Perform association analysis using R packages such as ggstatsplot

  • Analyze RNA-seq data from public databases (TCGA, CGGA, GEO) to investigate correlations between MLLT11 expression and immune cell markers

• Experimental validation:

  • Perform qPCR analysis of MLLT11 and key immune cell markers (CD206, CD163, ARG1, CD115, IL-10) in tissue samples

  • Conduct dual immunohistochemistry for MLLT11 and immune cell markers (e.g., CD163 for M2 macrophages)

  • Use Western blotting to quantify protein levels of MLLT11 and immune markers

• Correlation analysis:

  • Employ Pearson correlation analysis to identify immune cells strongly associated with MLLT11 expression (|r| > 0.4, p < 0.05)

  • Focus on relationships with specific immune cell populations, such as naive CD4+ T cells, CD8+ T cells, and M2 macrophages

Research has shown that MLLT11 expression correlates positively with infiltration of naive CD4+ T cells and CD8+ T cells while negatively correlating with macrophage infiltration, particularly M2 macrophages, in glioma tissues .

What approaches can be used to study MLLT11's role in neuronal development?

To investigate MLLT11's function in neuronal development, particularly in cortical projection neurons, researchers have successfully implemented these methodologies:

• In utero electroporation:

  • Design appropriate MLLT11 expression or knockdown constructs

  • Perform in utero electroporation at specific embryonic stages

  • Analyze neuronal migration, morphology, and connectivity in developing cortex

• Primary neuronal cultures:

  • Isolate cortical neurons from embryonic mice

  • Manipulate MLLT11 expression through transfection or viral transduction

  • Assess neurite outgrowth and morphological parameters

• Molecular analysis:

  • Use MLLT11 conditional knockout (cKO) models

  • Extract RNA from cortices at specific developmental timepoints (e.g., E18.5)

  • Perform qPCR to confirm loss of MLLT11 transcripts

  • Analyze protein expression through Western blotting using anti-acetylated tubulin and anti-MLLT11 antibodies

These approaches have revealed MLLT11's critical role in regulating migration and neurite outgrowth of callosal projection neurons during brain development, providing insights into its function in neuronal connectivity formation.

How can researchers validate the specificity of MLLT11 antibodies?

To ensure antibody specificity and reliability, researchers should implement a combination of validation methods:

• Standard validation:

  • Assess concordance with available experimental gene/protein characterization data in UniProtKB/Swiss-Prot database

  • Validation results can be classified as Supported, Approved, or Uncertain

• Enhanced validation methods:

  • siRNA knockdown: Evaluate decrease in antibody-based staining intensity upon target protein downregulation

  • Tagged GFP cell lines: Evaluate signal overlap between antibody staining and GFP-tagged protein

  • Independent antibodies: Compare staining patterns of two or more independent antibodies directed toward different epitopes on MLLT11

• Technical validation in experimental systems:

  • Conduct Western blot analysis in tissues with known MLLT11 expression profiles

  • Include positive controls (Jurkat, K562, or Molt4 cell lysates) and negative controls

  • Verify band sizes match predicted molecular weights (10 kDa and 36 kDa)

These validation approaches should be documented to support the reliability and reproducibility of experimental findings related to MLLT11 expression and function.

What factors might affect reproducibility in MLLT11 antibody-based experiments?

Several factors can influence the reproducibility of results when working with MLLT11 antibodies:

• Antibody selection and quality:

  • Source and type (monoclonal vs. polyclonal)

  • Validation status (standard vs. enhanced validation)

  • Lot-to-lot variability

  • Storage conditions and antibody age

• Sample preparation variables:

  • Fixation protocols (duration, fixative type)

  • Antigen retrieval methods (heat-induced vs. enzymatic)

  • Blocking reagents and duration

  • Antibody incubation conditions (temperature, duration)

• Technical considerations:

  • Antibody dilution optimization

  • Secondary antibody selection

  • Detection system sensitivity

  • Imaging parameters and quantification methods

• Biological variables:

  • Tissue heterogeneity

  • Developmental stage differences

  • Pathological state variations

  • Species-specific differences in MLLT11 expression

Careful documentation of these variables and standardization of protocols across experiments can significantly improve reproducibility in MLLT11 antibody-based research.

How should researchers interpret differences in MLLT11 expression across various tumor grades?

When analyzing MLLT11 expression across different tumor grades, particularly in gliomas, researchers should consider the following interpretative framework:

• Quantitative assessment:

  • Use standardized scoring methods for immunohistochemistry (IHC) using image processing software such as ImageJ

  • Perform statistical analysis to determine significance of expression differences between grades

  • Correlate protein expression (IHC) with mRNA expression (qPCR) data

• Correlation with pathological features:

  • Analyze MLLT11 expression in context of histopathological parameters

  • Consider molecular subtypes based on established classification systems (e.g., Verhaak bulk and Neftel single-cell classification)

  • Conduct Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis to identify associated biological processes

• Prognostic significance:

  • Perform Kaplan-Meier survival analysis and Cox regression analysis

  • Evaluate MLLT11 as an independent prognostic factor

  • Consider correlation with established prognostic markers

• Immune contextualization:

  • Analyze MLLT11 expression in relation to tumor-associated immune cells

  • Consider correlation with M2 macrophage markers (CD206, CD163, ARG1) which have been shown to increase with tumor grade alongside changes in MLLT11 expression

These analytical approaches provide a comprehensive framework for interpreting the biological and clinical significance of MLLT11 expression patterns across tumor grades.

What are emerging applications for MLLT11 antibodies in cancer research?

Based on recent findings about MLLT11's role in gliomas, several promising research directions are emerging:

• Therapeutic target identification:

  • Using MLLT11 antibodies to evaluate potential drug efficacy in preclinical models

  • Monitoring MLLT11 expression changes in response to treatment

  • Developing MLLT11-targeted therapeutic approaches

• Immunotherapy biomarker development:

  • Investigating MLLT11's relationship with immune checkpoint molecules

  • Utilizing MLLT11 expression as a predictive marker for immunotherapy response

  • Combining MLLT11 with other markers to create comprehensive immune profiles of tumors

• Single-cell analysis:

  • Applying MLLT11 antibodies in single-cell protein profiling techniques

  • Correlating MLLT11 expression with cellular heterogeneity in tumors

  • Mapping MLLT11 expression to specific cell subpopulations within the tumor microenvironment

These applications represent the cutting edge of MLLT11 research in oncology and provide valuable opportunities for developing new diagnostic and therapeutic approaches.

How can MLLT11 antibodies contribute to understanding neurodevelopmental disorders?

Given MLLT11's role in neuronal migration and neurite outgrowth, antibody-based studies may provide insights into neurodevelopmental disorders:

• Developmental expression mapping:

  • Characterizing spatiotemporal expression patterns of MLLT11 in developing brain

  • Identifying critical periods where MLLT11 function may impact neuronal connectivity

  • Comparing expression patterns in normal versus pathological development

• Circuit-specific analysis:

  • Using MLLT11 antibodies to study specific neuronal populations affected in neurodevelopmental disorders

  • Investigating callosal projection neurons and their connectivity patterns

  • Correlating MLLT11 expression with functional circuit development

• Genetic model validation:

  • Confirming phenotypes in MLLT11 conditional knockout models

  • Analyzing cellular and molecular consequences of MLLT11 dysfunction

  • Validating potential therapeutic interventions targeting MLLT11-related pathways

These approaches may reveal novel mechanisms underlying neurodevelopmental disorders and identify potential therapeutic targets for conditions involving aberrant neuronal migration or connectivity.